17-31517796-G-A
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_032932.6(RAB11FIP4):c.482G>A(p.Ser161Asn) variant causes a missense change. The variant allele was found at a frequency of 0.00000193 in 1,555,990 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 11/19 in silico tools predict a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Consequence
NM_032932.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RAB11FIP4 | NM_032932.6 | c.482G>A | p.Ser161Asn | missense_variant | 4/15 | ENST00000621161.5 | NP_116321.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAB11FIP4 | ENST00000621161.5 | c.482G>A | p.Ser161Asn | missense_variant | 4/15 | 1 | NM_032932.6 | ENSP00000482620.1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152142Hom.: 0 Cov.: 30
GnomAD3 exomes AF: 0.0000125 AC: 2AN: 159928Hom.: 0 AF XY: 0.0000237 AC XY: 2AN XY: 84468
GnomAD4 exome AF: 0.00000142 AC: 2AN: 1403730Hom.: 0 Cov.: 34 AF XY: 0.00000144 AC XY: 1AN XY: 692608
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152260Hom.: 0 Cov.: 30 AF XY: 0.0000134 AC XY: 1AN XY: 74450
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 05, 2024 | The c.482G>A (p.S161N) alteration is located in exon 4 (coding exon 4) of the RAB11FIP4 gene. This alteration results from a G to A substitution at nucleotide position 482, causing the serine (S) at amino acid position 161 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at